scorecardresearch
Friday, March 29, 2024
TopicRemdesivir

Topic: Remdesivir

Dexamethasone, favipiravir, plasma therapy — how India’s Covid care has evolved in 5 months

From uncertainty on how to treat patients in the first few weeks to now using steroids such as dexamethasone, a lot has changed in Covid care over the last 5 months.  

Gilead has got it right with the pricing of remdesivir for Covid treatment

Gilead CEO Daniel O'Day wrote in an open letter that the drug's ability to reduce hospital stays by four days equates to savings of $12,000 per patient in the US

Gilead says remdesivir will cost $2,340 for 5-day course

Gilead said it would offer this price to developed countries around the world in order to create a one-price model that would avoid country-by-country negotiations that could slow down access.

Remdesivir included as ‘investigational therapy’ for emergency Covid use: Health Ministry

The health ministry said the emergency use of Remdesivir may be considered in patients on oxygen but with no specified contraindications.

Health ministry revises stance on HCQ for Covid treatment, allows remdesivir for emergency use

In a new set of protocols, the ministry backtracked from its earlier stance and recommended HCQ in the early course of the disease but not in severe cases.

Dr Reddy’s signs deal with Gilead to register, manufacture and sell Remdesivir in India

The non-exclusive licensing agreement covers 127 countries, including India. Remdesivir is currently approved in the US for the emergency Covid treatment.

US’ Gilead Sciences enters India to boost supply of potential Covid drug remdesivir

Gilead Sciences says it will ‘work closely with the health authorities in India to provide guidance on anticipated drug supply based on local incidence and severity of disease’.

Face scan, open doors, zig-zag seating, doctor-on-call: Pharma firms redefine Covid workplace

The pharmaceutical industry has functioned throughout the lockdown and as such is leading the way in creating a safe workplace amid Covid-19 pandemic. 

Remdesivir cuts recovery time of Covid patients from 15 days to 11: New peer-reviewed study

The study, conducted on over 1,000 patients, also found that remdesivir is unlikely to be sufficient as a standalone treatment as it didn't significantly reduce the death rate.

Remdesivir mainly helped healthier Covid-19 patients heal faster, study finds

While a fuller analysis is still underway, researchers said it’s already clear that antiviral drugs like remdesivir alone won’t control the outbreak.

On Camera

Profit margins in lottery industry are tiny. Here’s how Future Gaming paid for its electoral bonds

Neither state govts nor companies earn large profits from lotteries. However, a look at the system shows there’s ample evidence of murky dealings and financial irregularities. 

Amid plans to lift AFSPA, Army starts joint training with Jammu & Kashmir Police

In an interview with Gulistan News this week, Union Home Minister Amit Shah said the government would leave law and order to J&K Police and slowly withdraw troops.

For BJP, Kejriwal is an idea whose time has come to be destroyed

The ‘idea’ Kejriwal's politics grew around was a no-holds-barred fight against corruption. That is the reason Modi govt has now tarred him and his entire party with the same paint.